CTI BioPharma Corp. (CTIC)

0.72
NASDAQ : Health Technology
Prev Close 0.74
Day Low/High 0.70 / 0.75
52 Wk Low/High 0.60 / 1.76
Avg Volume 102.60K
Exchange NASDAQ
Shares Outstanding 57.98M
Market Cap 42.79M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Weekend Reading: Optimists Still Have Hope

After getting dinged by the U.S. trade deficit, the market should keep ticking along next week on quarterly reports.

Health Stocks in Motion

Health Stocks in Motion

DaVita falls after disclosing a subpoena.

Cell Therapeutics Crushed

Cell Therapeutics Crushed

The biotech releases disappointing test data for its cancer drug.

Health Stocks in Motion

Health Stocks in Motion

Biogen and Elan lead the sector lower after Tysabri is pulled.

Cell Therapeutics' Deal Begs $18 Million Questions

Cell Therapeutics' Deal Begs $18 Million Questions

The company's been oddly promotional throughout the Stellar 3 study, and this deal adds to the wonder.

UBS Global Life Sciences: Day 1 Notebook

Some notes and observations on Monday's activity at the UBS Global Life Sciences conference.

Investors Twice Shy on Cell Therapeutics

Investors Twice Shy on Cell Therapeutics

It's not surprising the stock is down since May, when the company dropped bullish hints about Xyotax.

Cell Therapeutics Gets FDA OK

Cell Therapeutics Gets FDA OK

The comany gets fast track approval status for its non-Hodgkin's lymphoma.

UnitedHealth Board Has Generosity in Its Blood

UnitedHealth Board Has Generosity in Its Blood

The HMO's execs have made out well with a rising stock, thanks in part to massive stock-option grants.

Cell Therapeutics Jumps on Study Data

Cell Therapeutics Jumps on Study Data

Response rates are high for its Xyotax in combination with platinates against tumors.

The Theory of Trading Relativity

It's crucial to form your own definition of a significant stock move.

Rates Look Ready to Cool

According to the chart, they'll halt their rise. Plus, Take-Two, Freddie Mac and more.

Investor Hands Out a Giant Slice of Genta

The question is what's behind Paramount's disbursement of 5.5 million shares to its investors.

Fast Track Doesn't Equal Sure Thing

Biotech firms use fast-track approval to get stocks moving up.

What Were They Thinking at Cell Therapeutics?

Investors expecting a big European deal got a merger with a no-name company and a $100 million convertible.

Cell Therapeutics to Buy Italian Cancer Drug Developer

The company will acquire Novuspharma for about $236 million in stock.

Cell Therapeutics Rises on Drug's Fast-Track Designation

Its Xyotax is in phase II trials for non-small cell lung cancer.

Intermune Sinks, but Generics Find Buyers

The broader biotech sector measures are moving slightly lower.

Recognize Your Limits

No matter how much you think you know, it's better to trade what you see, rather than what you believe.

A Disappearing Act at Cell Therapeutics

A Disappearing Act at Cell Therapeutics

Investors had to look closely to discover the departure of two top executives.

The SEC Is Curious About the ASCO Effect

The SEC Is Curious About the ASCO Effect

Regulators seek information on how the American Society of Clinical Oncology releases research abstracts.

Red Flags in the Filings

Soon-to-be-filed proxies and annual reports can reveal some startling corporate behavior.

Biotech's Biggest May Also Be Its Best Right Now

Amgen appears to have a lot going for it. And Genzyme is starting to look like a turnaround.

ASCO Again Aims to Plug Information Leak

ASCO Again Aims to Plug Information Leak

The influential clinical oncology society tries to squelch the 'ASCO effect' by withholding abstracts until its meeting.

Sonus May Score With New Taxol Formula

Sonus May Score With New Taxol Formula

Midstage results show the company's reformulated version got good responses to four cancers.

Risk and Potential Reward in Cell Therapeutics

Xyotax is not a sure thing, but some see high risk and high return in the reformulated cancer drug.

Look for These Opportunities in Biotech

Amid signs the sector may finally have bottomed, here are some names that bear further watching.

Enthusiasm Wilts for Biotech and Pharma

Enthusiasm Wilts for Biotech and Pharma

Some of yesterday's gains are evaporating as the day goes on.

Bantering About the Virtues of Breakouts

The Chartman offers his take on their use. Plus, charts of Disney, Boeing and more.

Cell Therapeutics Fighting the Buzz Over Cancer Compound

Cell Therapeutics Fighting the Buzz Over Cancer Compound

The stock has dropped more than 23% over the negative interpretation of leaked research.

TheStreet Quant Rating: D (Sell)